论文部分内容阅读
自首次报道以来，新型冠状病毒(2019 novel coronavirus，2019-nCoV)引起的新型冠状病毒肺炎已迅速在全球传播。2019-nCoV感染可引起严重肺炎，危及患者生命，目前尚无特效药物。2019-nCoV刺突蛋白及其受体血管紧张素转化酶2的结构已获得解析，为药物的开发提供了基础。通过人外周血单B细胞抗体筛选技术及其他抗体筛选技术，已获得多种针对2019-nCoV的中和抗体。抗体药物的开发为新型冠状病毒肺炎的预防和治疗提供了新的选择。此文简要综述抗2019-nCoV抗体类药物的研究开发。“,”Since first reported, COVID-19 caused by 2019 novel coronavirus (2019-nCoV) infection has spread rapidly around the world. 2019-nCoV can result in severe pneumonia and endanger patients’ lives. Currently, there are no specific drugs for 2019-nCoV infection. The structures of 2019-nCoV spike protein and its receptor angiotension-converting enzyme 2 have been resolved, providing basis for drug development. Many 2019-nCoV-specific neutralizing antibodies have been obtained by single B cell antibody technology from human peripheral blood as well as other antibody screening technologies. The development of antibody drugs provides new options for the prevention and treatment of COVID-19. This article briefly reviews the research and development of antibody drugs for 2019-nCoV.